Yttrium-90 and Rhenium-188 radiopharmaceuticals for radionuclide therapy

A key requirement for the effective implementation of the therapeutic approach, based on the intravenous administration of radiolabelled compounds (radionuclide therapy), is the sufficient availability of radionuclides with appropriate physical characteristics. Based on their nuclear properties, 188...

Descripción completa

Guardado en:
Detalles Bibliográficos
Otros Autores: International Atomic Energy Agency.
Formato: Sin ejemplares
Lenguaje:Inglés
Publicado: Vienna : IAEA, 2015.
Colección:IAEA Radioisotopes and Radiopharmaceuticals Series, no. 5
Materias:
Acceso en línea:Texto completo
Tapa
LEADER 02401nam#a22003975a#4500
001 BCCAB018074
008 150814s2015####au#a###fsb####001#0#eng#d
005 20151112103700.0
003 AR-BCCAB
245 0 0 |a Yttrium-90 and Rhenium-188 radiopharmaceuticals for radionuclide therapy  |h [recurso electrónico] /  |c International Atomic Energy Agency. 
260 # # |a Vienna :  |b IAEA,  |c 2015. 
300 # # |a 301 p. :  |b il. (algunas col.) ;  |c 24 cm. 
490 0 # |a IAEA Radioisotopes and Radiopharmaceuticals Series,  |x 2077-6462 ;  |v no. 5 
500 # # |a STI/PUB/1662. 
500 # # |a Título tomado de la versión electrónica (consultado: 14.08.15). 
504 # # |a Includes bibliographical references. 
520 # # |a A key requirement for the effective implementation of the therapeutic approach, based on the intravenous administration of radiolabelled compounds (radionuclide therapy), is the sufficient availability of radionuclides with appropriate physical characteristics. Based on their nuclear properties, 188Re and 90Y are considered among the most interesting radionuclides for therapy. Furthermore, they are produced through portable generators, which give opportunities for ensuring a worldwide distribution of these radionuclides. This publication illustrates recent studies aimed at investigating efficient quality control methods to ensure both the radionuclidic purity of generator eluates, and the proper preparation of new target specific 188Re and 90Y radiopharmaceuticals for various clinical applications. 
538 # # |a Modo de acceso: World Wide Web. 
020 # # |a 9789201038142 
710 2 # |a International Atomic Energy Agency. 
080 # # |a 61:621.039 
650 # 7 |a Radionuclide generators  |2 inist 
650 # 7 |a Radioisotopes  |2 inist 
650 # 7 |a Radiopharmaceuticals  |2 inist 
650 # 7 |a Yttrium - Isotopes - Therapeutic use  |2 inist 
650 # 7 |a Rhenium - Isotopes - Therapeutic use  |2 inist 
650 # 7 |a Radionucleidos  |2 inist 
650 # 7 |a Radisotopos  |2 inist 
650 # 7 |a Radiofarmacos  |2 inist 
650 # 7 |a Itrio  |2 inist 
650 # 7 |a Renio  |2 inist 
040 # # |a arbccab  |b spa 
856 4 0 |q pdf  |s 10.337 Kb  |u http://www-pub.iaea.org/MTCD/Publications/PDF/Pub1662web-89688003.pdf  |3 Texto completo 
856 4 0 |u http://campi.cab.cnea.gov.ar/tocs/tapas/p1662cov-54768397.jpg  |3 Tapa 
942 # # |c BK 
952 # # |2 udc  |7 NOT_LOAN  |a ARBCCAB  |b ARBCCAB  |i 018074_nuevo-0  |o Acceso Web  |p 018074_nuevo-0  |t 1  |y VM